Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
La Da
Institutions:
Second Hospital of Tianjin Medical University,
Tianjin Medical University
Observed institutions:
Second Hospital of Tianjin Medical University,
Tianjin Medical University
ORCID:
0000-0003-3625-6975
Observed ORCID:
0000-0003-3625-6975
OpenAlex ID:
A5005526339
Downregulated hsa_circ_0077837 and hsa_circ_0004826, facilitate bladder cancer progression and predict poor prognosis for bladder cancer patients
2020
·
Chong Shen
, Zhouliang Wu
, et al.
·
Cancer Medicine
·
53
PDF
Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancer
2022
·
Chong Shen
, Zhi Li
, et al.
·
Frontiers in Oncology
·
16
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
·
Clinical Cancer Research
·
12
PDF
Phase 2 Study of Preoperative Tislelizumab in Combination with Low-dose Nab-Paclitaxel in Patients with Muscle-invasive Bladder Cancer
2024
·
Zhouliang Wu
, Gangjian Zhao
, et al.
·
European Urology Oncology
·
10
Phase II clinical study of tislelizumab combined with nab-paclitaxel (TRUCE-01) for muscle-invasive urothelial bladder carcinoma: Bladder preservation subgroup analysis.
2022
·
Yuanjie Niu
, Hailong Hu
, et al.
·
Journal of Clinical Oncology
·
10
Expression and Prognostic Significance of the MMP Family Molecules in Bladder Cancer
2020
·
Chong Shen
, La Da
, et al.
·
Combinatorial Chemistry & High Throughput Screening
·
6
Long noncoding RNAs, ENST00000598996 and ENST00000524265, are correlated with favorable prognosis and act as potential tumor suppressors in bladder cancer
2020
·
Chong Shen
, Yujie Wang
, et al.
·
Oncology Reports
·
5
PDF
The CUSUM curve combined with comprehensive complication index for assessing short‐term complications of radical cystectomy
2022
·
Diansheng Zhou
, Jie Gao
, et al.
·
Journal of Clinical Laboratory Analysis
·
3
PDF
TRUCE-02: An open label, single-arm, phase II study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma.
2022
·
HaiTao Wang
, Hailong Hu
, et al.
·
Journal of Clinical Oncology
·
3
Pd10-07 Update of Truce-01: Neoadjuvant Tislelizumab Combined With Nab-paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
2022
·
Hailong Hu
, Yuanjie Niu
, et al.
·
The Journal of Urology
·
2
Clinical utility of urine tumor DNA in bladder cancer patients.
2022
·
Hailong Hu
, Yuanjie Niu
, et al.
·
Journal of Clinical Oncology
·
1
Data from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S5 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S4 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Variation of renal function in patients with urothelial carcinoma treated by tislelizumab-based immunochemotherapy.
2023
·
Zhouliang Wu
, Hailong Hu
, et al.
·
Journal of Clinical Oncology
PDF
Molecular classification for predicting the efficacy of neoadjuvant tislelizumab combining nab-paclitaxel in Chinese bladder cancer.
2022
·
Hailong Hu
, Yuanjie Niu
, et al.
·
Journal of Clinical Oncology
Mp59-19 Update of Truce-02: an Open Label, Single-arm, Phase 2 Study of Tilelizumab Combined With Nab-paclitaxel for High-risk Non-muscle-invasive Urothelial Bladder Carcinoma (hr-nmibc) Which Is Not Completely Resectable
2022
·
Hailong Hu
, Yuanjie Niu
, et al.
·
The Journal of Urology
LncRNA MNX-AS1 combined with YBX1 to promote bladder cancer proliferation, migration, and invasion through activiting Wnt signaling pathway
2021
·
Hailong Hu
, Zhouliang Wu
, et al.
PDF
Show more works
View as search
Works count:
23
Citation count:
121
H-index:
6
I10-index:
5
Year
Topic
Type